AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Calquence (acalabrutinib) by Year
Calquence (acalabrutinib) — Established RoW YoY CER (%) (%)
AstraZeneca Calquence (acalabrutinib): 27.0% in FY2025, up 5.0 pts from a year earlier.
Latest, FY2025
27.0%
Period ended Dec 31, 2025
Change on a year earlier
+5.0 pts
22.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Calquence | 3,518 | 12 | 12 | 2,339 | 7 | 233 | 52 | 54 | 784 | 20 | 15 | 162 | 25 | 27”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Calquence (acalabrutinib) — Established RoW YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.0% | +5.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 22.0% | -43.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 65.0% | – | Form 6-K FY2023Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Calquence (acalabrutinib) (%), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-erow-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.